Metastatic castration-resistant prostate cancer (mCRPC) remains a leading cause of cancer-related mortality in men. Although poly(ADP-ribose) polymerase (PARP) inhibitors are approved for mCRPC patients with homologous recombination repair (HRR) deficiencies, clinical trials combining olaparib with PD-1/PD-L1 inhibitor...
Ping Xie, Ren-Qiang Ma, Ming-Hui Zhang et al.· Journal of Clinical Investig...· 0 citations
This study identifies USP22 as a tumor-intrinsic suppressor of NK- and CD8+ T-cell—mediated antitumor immunity and reports a USP22-specific inhibitor with dual onco-targeting and immune-boosting activity, representing a first-in-class therapeutic strategy.
De-Yu Fang, Kun Liu· Journal of Immunology· 0 citations
This review synthesizes current evidence describing how USP22 modulates oncogenic transcriptional states and immune evasion and suggests that USP22 inhibition may offer a therapeutic strategy with dual effects on tumor biology and antitumor immunity.
Deyu Fang· Trends in Molecular Medicine· 0 citations
The first FoxP3-specific small molecule degrader which promotes proteasomal degradation of FoxP3 and partially reduces Treg suppressive function is reported, demonstrating proof-of-concept and feasibility of targeting FoxP3, which has been known to be “undruggable”, in a chemical manner by small molecules.
Amy Y. Tang, Zhao-Meng Cai, Kun Liu et al.· Journal of Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
